15-ICML - 15th INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA
Lugano, Switzerland – June 18 – 22, 2019
www.lymphcon.ch

SATELLITE SYMPOSIUM AGENDA (as of March 8, 2019)

Tuesday, June 18, 2019

13:30 – 15:00 *satellite symposium*

Room B I

KITE, A GILEAD COMPANY
CAR T: FROM BED TO BENCH AND BACK AGAIN
Chair: C. Roddie, London (United Kingdom)

16:00 – 17:30 *3 parallel symposia*

Room A

NOVARTIS ONCOLOGY
MAXIMIZING CLINICAL BENEFIT IN LYMPHOMAS: EXPLORING THE UTILITY OF CAR T-CELL THERAPY
Chair: U. Jaeger, Vienna (Austria)

In the satellite symposium "Maximizing Clinical Benefit in Lymphomas: Exploring the Utility of CAR-T Cell Therapy," Dr. Ulrich Jaeger (chair) and additional faculty will lead an interactive discussion regarding the role of CAR-T cell therapy in lymphomas. Key themes addressed will include defining the diffuse large B-cell lymphoma continuum of care and best practices for adverse event management; in addition, the potential future utility of CAR-T cell therapy in non-Hodgkin lymphoma – including combination partners, use in earlier lines of therapy, and role for pediatric patients – will be covered.

16:00 – 16:05 INTRODUCTIONS AND OPENING REMARKS
U. Jaeger, Vienna (Austria)

16:05 – 16:25 DEFINING THE UTILITY OF CAR-T CELL THERAPY IN THE DLBCL CONTINUUM OF CARE
U. Jaeger, Vienna (Austria)

16:25 – 16:45 PRACTICAL CONSIDERATIONS FOR TOXICITY MANAGEMENT WITH CAR-T CELL THERAPY
J. Westin, Houston, TX (USA)

16:45 – 17:00 EXPLORING ADDITIONAL ROLES FOR CAR-T CELL THERAPY IN NHL
A. Sureda, Barcelona (Spain)

17:00 – 17:15 RATIONALE AND FUTURE DIRECTIONS FOR CAR-T CELL THERAPY IN PEDIATRIC NHL
B. Burkhardt, Münster (Germany)

17 :15 – 17 :25 PANEL DISCUSSION AND Q&A
All

17:25 – 17:30 CLOSING REMARKS
U. Jaeger, Vienna (Austria)

Room B I

BRISTOL-MYERS SQUIBB

RATIONALE: RESEARCH AND NEW THERAPEUTIC APPROACHES – I-O NOVEL AGENTS ADVANCING LYMPHOMA EXPECTATIONS

Chair: P.L. Zinzani, Bologna (Italy)

This symposium, sponsored by Bristol-Myers Squibb, describes recent advances in treating patients with lymphoma using immuno-oncology (I-O) agents and the utilization of biomarkers to further understand the underlying disease biology and inform novel targeting strategies. Following an introduction to I-O clinical trial advances and ongoing investigations, there will be a discussion of recent key data in salvage and maintenance settings and their potential impact on post-transplant treatment. The final presentation will focus on the potential of biomarkers in lymphoma to inform future clinical trials. A question-and-answer session will provide an opportunity for the participants to interact with the faculty experts.

16:00 – 16:05 WELCOME AND INTRODUCTIONS
P.L. Zinzani, Bologna (Italy)

16:05 – 16:25 ONGOING IMMUNO-ONCOLOGY EXPLORATIONS IN LYMPHOMA
P.L. Zinzani, Bologna (Italy)

16:25 – 16:45 OPTIMIZING PERI-TRANSPLANT THERAPY WITH IMMUNO-ONCOLOGY
A. Herrera, Duarte, CA (USA)

16:45 – 17:05 BIOMARKER DISCOVERY IN LYMPHOMA
To be announced

17:05 – 17:25 OPEN DISCUSSION WITH THE EXPERTS
All

17:25 – 17:30 CLOSING REMARKS
P.L. Zinzani, Bologna (Italy)

Room B II

KITE, A GILEAD COMPANY

CAR T THERAPY: A CLOSER LOOK AT THE SCIENCE BEHIND THE CELLS

Chair: M. Topp, Würzburg (Germany)

18:30 – 20:00 *4 parallel symposia*

Room A

ROCHE

ANTIBODY THERAPIES FOR PATIENTS WITH DLBCL: WHAT DOES THE FUTURE HOLD?

Chair: L. Sehn, Vancouver B.C. (Canada)

While many patients with diffuse large B-cell lymphoma (DLBCL) can be cured with current front-line therapy, a significant proportion relapse or are refractory to treatment. High-dose chemotherapy and stem-cell transplantation are possible for some of these patients, but many are ineligible due to co-morbidities or disease refractory to chemotherapy; these patients face a dismal outcome. An international faculty of experts will discuss treatment and management of both front-line and relapsed/refractory DLBCL, with a focus on novel antibody therapies. Join us to examine how the DLBCL landscape may evolve in the near future as new data and treatment options become available.

18 :30 – 18 :35 INTRODUCTION
L. Sehn, Vancouver B.C. (Canada)

18 :35 – 18 :45 WHAT OPTIONS DO OUR PATIENTS HAVE FOR FIRST-LINE TREATMENT?
A. Lopez Guillermo, Barcelona (Spain)

18:45 – 18:55 WHAT'S NEXT FOR PATIENTS WHO RELAPSE OR ARE REFRACTORY TO TREATMENT?
M.J. Matasar, New York, NY (USA)

18:55 – 19:10 CAN NOVEL ANTIBODY THERAPIES IMPROVE OUTCOMES FOR PATIENTS WITH R/R DLBCL?
F. Morschhauser, Lille (France)

19:10 – 19:25 POLATUZUMAB VEDOTIN: CLINICAL DATA IN R/R DLBCL
L. Sehn, Vancouver B.C. (Canada)

19 :25 -19 :40 WHAT MIGHT THE FUTURE HOLD FOR DLBCL TREATMENT STRATEGIES?
A. McMillan, Nottingham (UK)

19:40 – 19:55 PANEL DISCUSSION
All

19:55 – 20:00 CLOSING REMARKS
L. Sehn, Vancouver B.C. (Canada)

Room B I **BAYER**

PRECISION MEDICINE IN MALIGNANT LYMPHOMA: IS IT A REALITY?

Chair: M. Ghielmini, Bellinzona (Switzerland)

Precision medicine has traditionally been a personalized approach to the treatment of solid tumors with the advent of biomarker-driven strategies. However, when it comes to the treatment of malignant lymphoma, is precision medicine a reality? Join the esteemed faculty Dr. Michele Ghielmini, Dr. Margaret Shipp, Dr. Louis Staudt, and Professor Martin Dreyling in their invigorating exploration of genetic heterogeneity in aggressive lymphoma, clinical exploration of precision medicine in DLBCL, and enrichment strategies in indolent lymphoma with the aim of uncovering whether precision medicine is a reality in malignant lymphoma.

WELCOME AND OPENING REMARKS
M. Ghielmini, Bellinzona (Switzerland)

GENETIC HETEROGENEITY IN AGGRESSIVE LYMPHOMA AND POTENTIAL THERAPEUTIC IMPLICATIONS
M. Shipp, Boston, MA (USA)

CLINICAL EXPLORATION OF PRECISION MEDICINE IN DLBCL
L. Staudt, Bethesda, MD (USA)

ENRICHMENT STRATEGIES IN INDOLENT LYMPHOMA
M. Dreyling, Munich (Germany)

PANEL DISCUSSION/Q&A
Chair: M. Ghielmini, Bellinzona (Switzerland)

Room B II

TAKEDA ONCOLOGY

ON THE FRONTLINE: MANAGING PATIENTS WITH CD30+ HL AND PTCL

Chair: M. Hutchings, Copenhagen (Denmark)

HISTORICAL PERSPECTIVE ON FRONTLINE TREATMENT LANDSCAPE FOR HL
To be announced

NEW TARGETED TREATMENT OPTIONS FOR FRONTLINE HL
To be announced

USE OF CD30 DIRECTED THERAPY TO IMPROVE TREATMENT OUTCOMES IN NEWLY DIAGNOSED PTCL
To be announced

CONCLUSIONS
To be announced

PANEL DISCUSSION/Q&A
To be announced

Auditorium, University

LYMPHOMA HUB

NEW CHEMOTHERAPY-FREE APPROACHES FOR THE TREATMENT OF LYMPHOID MALIGNANCES

Chair and co-chair: G. Salles, Lyon (France) and A. Younes, New York, NY (USA)

18:30–18:35 OBJECTIVES AND INTRODUCTIONS
G. Salles, Lyon (France)

18:35 -18:45 DLBCL – CHEMOTHERAPY-FREE REGIMENS: PROS AND CONS
U. Jäger, Vienna (Austria)

18:45 –18:55 ROUND TABLE ON DLBCL
All

18:55 –19:05 FL – CHEMOTHERAPY-FREE REGIMENS: PROS AND CONS
N. Fowler, Houston, TX (USA)

19:05 –19:15 ROUND TABLE ON FL
All

19:15–19:25 MCL – CHEMOTHERAPY-FREE REGIMENS: PROS AND CONS
S. Rule, Plymouth (UK)

19:25 –19:35 ROUND TABLE ON MCL
All

19:35 – 19:45 CLL – CHEMOTHERAPY-FREE REGIMENS: PROS AND CONS
M. Hallek, Cologne (Germany)

19:45 – 19:55 ROUND TABLE ON CLL
All

19:55 – 20:00 MEETING CONCLUSION
A. Younes, New York, NY (USA)

Wednesday, June 19, 2019

18:30 – 20:00 *3 parallel symposia*

Room A **JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON**

CHALLENGING THE STANDARDS OF CARE IN THE MANAGEMENT OF PATIENTS WITH B-CELL LYMPHOMAS

Chair: C. Buske, Ulm (Germany)

Therapeutic advances in lymphoma have been made over many decades. A deeper understanding of disease pathogenesis guided the development of targeted therapies for patients with MCL and WM. Consequently, providing tolerable and curative therapies to many lymphoma patients is now possible. However, some specific challenges still remain, including limited investigations into rare lymphoma subtypes and using backbone chemotherapy regimens for initial therapy. Our faculty will discuss studies challenging current standards of care and the potential to improve patient outcomes in various B-cell lymphomas.

18:30-18:40 WELCOME AND INTRODUCTIONS
C. Buske, Ulm (Germany)

18:40-19:00 HOW TARGETED THERAPIES ARE IMPACTING THE MANAGEMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL)
S. Rule, Plymouth (UK)

19:00 – 19:20 CAN WE IMPROVE ON R-CHOP FOR PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)?
G. Lenz, Münster (Germany)

19:20 – 19:40 HARMONIZING SCIENTIFIC RESEARCH WITH CLINICAL PRACTICE IN WALDENSTRÖM'S MACROGLOBULINEMIA
S. Treon, Boston, MA (USA)

19:40 – 20:00 PANEL DISCUSSION AND CLOSING REMARKS
C. Buske, Ulm (Germany) and all

Room B **MEDSCAPE EDUCATION**

CHALLENGING CURRENT PARADIGMS IN CLL: TIME AND TREATMENT

Supported by an independent educational grant from AbbVie

Chair: P. Hillmen, Leeds (UK)

The concept of time-limited therapy is not new; chemotherapy regimens are of fixed duration. However, recent years have seen the emergence of therapies, such as Bruton tyrosine kinase (BTK) inhibitors, which require continuous treatment. In contrast, B-cell lymphoma 2 (Bcl-2)-inhibitor combinations have been developed as 2-year and 1-year fixed-duration therapies, offering new time-limited treatment options. Furthermore, both approaches are – or will potentially be – approved in

both front-line and relapse settings, challenging both initial treatment selection and sequencing decisions.
This symposium explores the current and emerging treatment paths for patients with treatment-naive chronic lymphocytic leukemia (CLL) and the impact of initial choices on treatment options in relapse.

18:30 – 18:40 WELCOME AND INTRODUCTION
P. Hillmen, Leeds (United Kingdom)

18:40-19:00 NOVEL CONCEPTS IN CLL PRACTICE
To be confirmed

19:00-19:20 CURRENT AND EMERGING PARADIGMS: TIME-LIMITED THERAPY
B. Eichhorst, Cologne (Germany)

19:20-19:40 CURRENT AND EMERGING PARADIGMS: CHRONIC THERAPY
M. Davids, Boston, MA (USA)

19:40-20:00 CHALLENGES IN PRACTICE: INITIAL TREATMENT SELECTION AND SEQUENCING THERAPY
Panel and Audience Debate

Auditorium, University

SANDOZ ONCOLOGY

VARIABILITY OF BIOLOGICS AND ITS IMPACT ON BIOSIMILAR DEVELOPMENT
Chair: W. Jurczak, Krakow (Poland)

Biologics are highly complex to manufacture and their immunogenicity, tolerability, and efficacy profiles can be affected by significant manufacturing process changes. As such, manufacturing changes must be carefully monitored at every step, in order to ensure the correct product identity throughout the lifecycle.
Biosimilars are developed using highly sensitive analytical methods and tailored clinical programs. The advent of biosimilars allowed for a much more detailed analysis of batch-to-batch variability and manufacturing shifts of reference medicines. Recently, some shifts in quality attributes of reference medicines have been reported by biosimilar manufacturers.
The faculty will discuss the potential impact of biologic variability on clinical outcomes and biosimilar development.
(References available on request)

18:30 – 18:45 THE CLINICIAN'S PERSPECTIVE
W. Jurczak, Krakow (Poland)

18:45 – 19:00 THE REGULATORY PERSPECTIVE
H. Schellekens, Utrecht (The Netherlands)

19:00 – 19:15 THE ANALYTICAL PERSPECTIVE
P. Cornes, Bristol (UK)

19:15 – 20:00 DEBATE AND Q&A
All faculty

Thursday, June 20, 2019

18:30 – 20:00 *2 parallel symposia*

Room A **CELGENE**

INDIVIDUALIZING TREATMENT AND EMERGING THERAPIES IN B-CELL MALIGNANCIES

Chair: U. Vitolo, Turin (Italy)

Recent clinical developments are transforming the treatment of indolent and aggressive B-cell malignancies. Chemotherapy-free therapies are altering the therapeutic landscape of both frontline and relapsed/refractory follicular lymphoma. Additionally, frontline treatment of diffuse large B-cell lymphoma is becoming increasingly individualized with a focus on selecting optimal therapies according to cell of origin. Meanwhile, the emergence of CAR T therapies for the treatment of various non-Hodgkin lymphomas and chronic lymphocytic leukemias have the potential to shift treatment paradigms entirely. Key emerging data in B-cell malignancies will be highlighted and discussed by experts in the field.

18:30-18:35 WELCOME AND INTRODUCTIONS
U. Vitolo, Turin (Italy)

18:35-18:55 TREATMENT IN THE CHEMOTHERAPY-FREE ERA IN FRONT-LINE AND RELAPSED AND REFRACTORY FOLLICULAR LYMPHOMA
J.P. Leonard, New York NY (USA)

18:55-19:15 OPTIMIZING FRONTLINE DLBCL TREATMENT: THE ROLE OF CELL OF ORIGIN
U. Vitolo, Turin (Italy)

19:15-19:35 EMERGING ROLE OF CAR T THERAPIES IN THE TREATMENT OF NHL AND CLL
D. Maloney, Seattle, WA (USA)

19:35 – 20:00 CLOSING AND Q&A
U. Vitolo, Turin (Italy) and All

Room B **MORPHOSYS**

SURVIVAL, SAFETY, SIMPLICITY: TRANSFORMING TREATMENT SEQUENCING IN DLBCL

Co-chairs: B.D. Cheson, Washington DC (USA) and G. Salles, Lyon (France)

Join us for this interactive symposium as we explore DLBCL treatment approaches: the progress made, remaining challenges, and the potential future of the treatment landscape. With an emphasis on the patient journey, we will seek to understand the issues faced beyond the first-line treatment setting, and hear expert insights to navigate real-world treatment decision-making challenges. In addition, through advances in DLBCL disease understanding, we will provide perspectives on how novel treatment approaches may be utilized to achieve new treatment strategies for patients who experience relapsed or refractory DLBCL.

18:30 – 18:35 WELCOME AND INTRODUCTION
Co-chairs: B.D. Cheson, Washington DC (USA) and G. Salles, Lyon (France)

18:35 – 18:45	DLBCL TREATMENT LANDSCAPE: CURRENT PERSPECTIVE G.S. Nowakowski, Rochester, MN (USA)
18:45 – 19:00	THE PATIENT JOURNEY: TREATMENT DECISION MAKING IN REAL-WORLD PRACTICE J. Westin, Houston, TX (USA)
19:00 – 19:10	PANEL DISCUSSION All
19:10 – 19:25	THE FUTURE FOR DLBCL: TRANSFORMING OUR APPROACHES AND TREATMENT SEQUENCING? A. Davies, Southampton (UK)
19:25 – 19:40	TARGETING CD19: A NOVEL ANTIBODY STRATEGY G. Salles, Lyon (France)
19:40 – 19:55	PANEL DISCUSSION All
19:55 – 20:00	SUMMARY AND CLOSE B.D. Cheson, Washington DC (USA)

Friday, June 21, 2019

Room A
18:30 – 19:30

ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND – IOSI
"THE BIG DEBATE: POINT COUNTER POINT"
ARE NEW EXPENSIVE ANTI-LYMPHOMA DRUGS WORTH THE MONEY?
Chair: M. Ghielmini, Bellinzona (Switzerland)
Supported by Gilead Sciences who provided funding.

Often targeted therapy, immunotherapy and CAR-T cells are registered at high price for indications for which they have at most demonstrated an increase in PFS and not in OS. The Big Debate, organized by the Oncology Institute of Southern Switzerland (IOSI) has become a tradition, and this year will discuss this issue. In three short debates, 6 distinguished speakers (10 minutes each) will argue, for three different lymphoma entities, if the results of new and expensive treatment do or not justify their very high costs.